Lisata Therapeutics cuts 72% of workforce, sues Kuva Labs over merger breach

LISATA THERAPEUTICS, INC.

Workforce reduced by ~72% effective immediately; estimated $1.2M in severance costs through Q3 2026.
CMO Dr. Kristen K. Buck terminated without cause; entitled to 12 months salary and bonus plus COBRA.
Company sued Kuva Labs in Delaware Chancery for breach of March 2026 merger agreement, seeking damages.
Retention bonus of $200k approved for SVP James Nisco, contingent on employment through Dec 31, 2026.
Company plans to pursue strategic options to maximize shareholder value.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.